Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - February 2013


3rd Patient Adherence and Advocacy Summit

25 Feb 2013 - 26 Feb 2013 - PA, USA



Bookmark and Share


The 2nd Patience Adherence Summit was a huge success with overwhelmingly positive feedback and comments from the audience evals. Our vision for the 3rd Patience Adherence and Advocacy Summit is to incorporate more of a patient-centric, patient-empowered focus as well as patient advocacy. The event will be very engaging and participant-oriented. Real-world scenarios and case studies will be featured and the audience will be fully engaged in learning and discovering innovative ideas on how to address and aid in the remedy of this devestaing industry-wide problem.

KEY LEARNING OBJECTIVES

Gain insightful new ideas to help Pharma understand why working with advocacy organizations not only makes good business sense, but how a patient can benefit from this collaboration as well

Understand how significant mobile technologies and digital platforms play in the rising adherence rates and how to incorporate these tools into your marketing plans

Leverage opportunities to work with government and non-profit agencies to better facilitate patient access to treatment

Recognize that extrinsic motivators are only short-lived and intrinsic motivators must be targeted for long-term behavior change

Determine the pharma-specific perceptions and rules that impact how industry works with advocacy groups

Incorporate your adherence messages with push and pull marketing



Further information
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!